Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety.

Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting. Am J Med (2016) 0.78

Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians. Clin Interv Aging (2017) 0.75

Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. Am J Cardiovasc Drugs (2015) 0.75

Improving Continuity of Care via the Discharge Summary. AMIA Annu Symp Proc (2015) 0.75

Recent publications by ochsner authors. Ochsner J (2013) 0.75

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Adherence to medication. N Engl J Med (2005) 39.77

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA (2001) 24.12

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23

ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 11.49

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med (1994) 10.26

Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med (1987) 8.09

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94

Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med (1995) 7.83

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ (2011) 5.84

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.57

Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48

Effect of home testing of international normalized ratio on clinical events. N Engl J Med (2010) 5.36

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.82

Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol (2010) 4.78

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45

Promoting effective transitions of care at hospital discharge: a review of key issues for hospitalists. J Hosp Med (2007) 4.09

Atrial fibrillation and cognitive disorders in older people. J Am Geriatr Soc (2000) 3.59

Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50

Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med (2003) 3.18

Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke (2005) 3.07

The care transitions intervention: translating from efficacy to effectiveness. Arch Intern Med (2011) 2.80

Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation (2011) 2.80

Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest (2006) 2.79

Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. JAMA (2011) 2.67

Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes (2008) 2.61

Dropping the baton: a qualitative analysis of failures during the transition from emergency department to inpatient care. Ann Emerg Med (2008) 2.53

2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2010) 2.48

Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health (2006) 2.44

Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke (2011) 2.20

Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm (2009) 2.08

Continuity of care matters. BMJ (2008) 2.07

National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med (2010) 1.89

Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis (2010) 1.83

Status of the epidemiology of atrial fibrillation. Med Clin North Am (2008) 1.80

Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol (2012) 1.79

Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med (2001) 1.69

Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med (2005) 1.61

Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J (2010) 1.55

Clinical experience with oral versus intravenous vitamin K for warfarin reversal. Transfusion (2012) 1.53

Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J (2006) 1.42

Persistence with stroke prevention medications 3 months after hospitalization. Arch Neurol (2010) 1.31

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis (2011) 1.30

Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol (2011) 1.27

Rates and implications for hospitalization of patients ≥65 years of age with atrial fibrillation/flutter. Am J Cardiol (2011) 1.20

Care transitions and home health care. Clin Geriatr Med (2009) 1.18

A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol (2001) 1.17

Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank. Arch Surg (2011) 1.16

Improving care transitions: hospitalists partnering with primary care. J Hosp Med (2010) 1.10

Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med (2003) 1.07

Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. Circulation (2010) 1.07

Superwarfarin poisoning: a report of two cases and review of the literature. Am J Hematol (2007) 1.07

New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost (2010) 1.06

Stroke prevention: modifying risk factors. Ther Adv Cardiovasc Dis (2008) 0.99

Update in bridging anticoagulation. J Thromb Thrombolysis (2011) 0.99

Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J (2011) 0.98

Clinical practice. Newly diagnosed atrial fibrillation. N Engl J Med (2004) 0.97

Racial and ethnic differences in warfarin response. J Heart Valve Dis (2004) 0.93

Strategies to improve care transitions between nursing homes and emergency departments. J Am Med Dir Assoc (2010) 0.93

Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy (2000) 0.85

Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. Thromb Res (2004) 0.83

Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department. Ann Pharmacother (2011) 0.80

Atrial fibrillation (AF) and cognitive impairment in the elderly: a case-control study. Arch Gerontol Geriatr (2011) 0.80

Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope. Eur Heart J (2011) 0.78

Prohemostatic agents to prevent perioperative blood loss. Semin Thromb Hemost (2008) 0.77

Care transitions from inpatient to outpatient settings: ongoing challenges and emerging best practices. Hosp Pract (1995) (2011) 0.76